LP(A) TESTING IN A REAL-WORLD POPULATION OF US ADULTS
Study PI(s): Neha Pagidipati and Emily O’Brien, Duke Clinical Research
Project Summary: Lipoprotein (a) [Lp(a)] is a strong marker for cardiovascular (CV) risk. Perhaps because there has not been a clear therapy for elevated Lp(a), this marker is rarely checked in practice. As novel therapies become available, it will be important to increase physician awareness and testing of Lp(a). First, we must understand which patients are having their Lp(a) checked in real-world settings, and what happens to these patients.
Our goals are to:
Study Design: Query based on data in the PCORnet® common data model (CDM) 4.1
Coordinating Center: Duke Clinical Research Institute